Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12623000458639
Ethics application status
Approved
Date submitted
14/04/2023
Date registered
3/05/2023
Date last updated
21/05/2024
Date data sharing statement initially provided
3/05/2023
Type of registration
Prospectively registered
Titles & IDs
Public title
The “New predictiVe factors that drIve coronary atheroscleroSIs follOwiNg Coronary Artery Disease (VISION-CAD)” study
Query!
Scientific title
The “New predictiVe factors that drIve coronary atheroscleroSIs follOwiNg Coronary Artery Disease (VISION-CAD)” study
Query!
Secondary ID [1]
309461
0
nil
Query!
Universal Trial Number (UTN)
U1111-1283-4500
Query!
Trial acronym
VISION-CAD
Query!
Linked study record
nil
Query!
Health condition
Health condition(s) or problem(s) studied:
Coronary artery disease
329715
0
Query!
Atherosclerosis
329716
0
Query!
Ischaemic heart disease
329717
0
Query!
Cardiovascular
329770
0
Query!
Condition category
Condition code
Cardiovascular
326613
326613
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Cardiovascular
326736
326736
0
0
Query!
Coronary heart disease
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
False
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Observation via serial CT coronary angiography (CTCA) and body composition scans with clinical and biomarker correlation.
1. CT scans will take approximately 20mins. Intravenous CT contrast dye will be injected based on body-weight, up to a maximum of 70mL. The procedure will be conducted by a Cardiologist, Radiographer, Nurse and Radiologist. There will be a second CT scan at 12 months.
2. Body composition scans will take 3minutes and involve three 5mm axial slices, through liver and spleen, mid abdomen (4th lumbar vertebra) and mid-thigh, at first CT scan and 12month CT scan.
The participants will be asked to provide biological samples at enrolment (first CT scan) and at 12 months (second CT scan), which will involve 50mL blood sample and optional faecal specimen.
The participants will be asked to complete questionnaires (quality of life, angina, pain) which will take 15 minutes, at enrollment, 6 months (via phone call or electronically) and at 12 months. Participants may be followed up at 3 and 5 years for additional phone-calls for questionnaires. Time-points are relative to the time of the first CT scan.
The CT scans will be performed at SA Health and Medical Research Institute Clinical Research and Imaging Centre.
Query!
Intervention code [1]
325883
0
Diagnosis / Prognosis
Query!
Comparator / control treatment
Baseline CT scans will be collected as part of this study.
CT scans will be compared from baseline to CT scans at 12 months.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
334472
0
Change in coronary plaque characteristics including progression via CT coronary angiography
Query!
Assessment method [1]
334472
0
Query!
Timepoint [1]
334472
0
12 months post-enrolment
Query!
Primary outcome [2]
334473
0
Changes in the glycome via mass spectometry of blood samples.
Query!
Assessment method [2]
334473
0
Query!
Timepoint [2]
334473
0
12 months post-enrolment
Query!
Primary outcome [3]
334474
0
Primary composite outcome of major cardiovascular outcomes - mortality, myocardial infarction, cardiac death, revascularisation, stroke, cardiovascular hospitalisation.
Via review of medical records, telephone interview, and interview in-person visit at 12 months for second CT scan.
Query!
Assessment method [3]
334474
0
Query!
Timepoint [3]
334474
0
12 months post enrolment.
Query!
Secondary outcome [1]
420815
0
Quality of life (EQ-5D-3L) questionnaire
Query!
Assessment method [1]
420815
0
Query!
Timepoint [1]
420815
0
At enrolment and 12 months post-enrolment
Query!
Secondary outcome [2]
421049
0
Angina questionnaire - SAQ-7
Query!
Assessment method [2]
421049
0
Query!
Timepoint [2]
421049
0
At enrolment and 12 months post-enrolment
Query!
Secondary outcome [3]
421050
0
Coronary plaque volume via CT coronary angiography with automated software or manual plaque analysis
Query!
Assessment method [3]
421050
0
Query!
Timepoint [3]
421050
0
12 months post-enrolment
Query!
Eligibility
Key inclusion criteria
• Subjects who have received a clinically indicated coronary angiogram for stable or unstable CAD, including stable angina, unstable angina and acute myocardial infarction (MI), comprising non-ST elevation MI (NSTEMI) or ST-elevation MI (STEMI).
• All subjects will be managed as per their treating clinicians, including with percutaneous coronary intervention (PCI) where indicated and use of antiplatelets, lipid-lowering medication (e.g. statins) and other guideline-recommended therapies.
• Eligible subjects will be those who at the time of angiography are identified as having at least one major coronary artery system (left main, left anterior descending, left circumflex, ramus intermedius or right coronary artery) that will be left with residual coronary plaque with no intention to revascularise this by PCI or bypass grafting for at least the next 12 months. Age 18 years or more at the time of screening.
• Able to provide informed consent to undergo non-invasive CTCA imaging within 30 days of their index angiogram and return for a follow-up CTCA 12±1 months later.
• Willingness to provide a blood sample (50 mL) around the time of their baseline and follow-up CTCA, and attend for an additional face-to-face study visit or receive a phone call at 6 months.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
• Any associated co-morbidity in which the life expectancy is <1 year.
• Dialysis or estimated glomerular filtration rate (eGFR) <30 ml/min/1.73m2
• Previous or planned coronary artery bypass grafting
• Active malignancy with ongoing or planned chemotherapy or radiation therapy
• Contraindications to CTCA
• Women of childbearing potential who are not partaking in contraception
• Unable to give informed consent
• Not willing or able to attend follow-up visits/repeat CTCA in 12 months
• Concurrent enrollment in a placebo-controlled trial or within 30 days of finishing a trial
• Any other information that the investigators consider will limit the ability of the participant to complete all study associated procedures and visits
Query!
Study design
Purpose
Natural history
Query!
Duration
Longitudinal
Query!
Selection
Defined population
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Linear and mixed regression models.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
5/05/2023
Query!
Actual
5/05/2023
Query!
Date of last participant enrolment
Anticipated
1/06/2024
Query!
Actual
Query!
Date of last data collection
Anticipated
30/06/2029
Query!
Actual
Query!
Sample size
Target
300
Query!
Accrual to date
3
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Recruitment hospital [1]
24534
0
The Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [2]
24535
0
The Queen Elizabeth Hospital - Woodville
Query!
Recruitment postcode(s) [1]
40126
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
40127
0
5011 - Woodville
Query!
Funding & Sponsors
Funding source category [1]
313655
0
Government body
Query!
Name [1]
313655
0
Department of Health and Aged Care, MRFF Cardiovascular Mission
Query!
Address [1]
313655
0
Department of Health and Aged Care
GPO Box 9848
Canberra ACT 2601
Australia
Query!
Country [1]
313655
0
Australia
Query!
Primary sponsor type
Other Collaborative groups
Query!
Name
South Australian Health and Medical Research Institute
Query!
Address
South Australian Health and Medical Research Institute
North Terrace, Adelaide SA 5000
Query!
Country
Australia
Query!
Secondary sponsor category [1]
315449
0
None
Query!
Name [1]
315449
0
Query!
Address [1]
315449
0
Query!
Country [1]
315449
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
312823
0
Central Adelaide Local Health Network (CALHN) Human Research Ethics Committee (HREC)
Query!
Ethics committee address [1]
312823
0
Royal Adelaide Hospital, Port Road, Adelaide SA 5000
Query!
Ethics committee country [1]
312823
0
Australia
Query!
Date submitted for ethics approval [1]
312823
0
17/01/2023
Query!
Approval date [1]
312823
0
16/02/2023
Query!
Ethics approval number [1]
312823
0
Query!
Summary
Brief summary
Hypothesis: In patients with coronary artery disease who are treated with guideline recommended therapies, ongoing progression and destabilisation of atherosclerotic plaques will be associated with previously unrecognised clinical, biological and mechanical factors that this prospective, natural history study seeks to identify.
Brief overview: This is a prospective, observational clinical study that will recruit participants undergoing clinically indicated coronary angiograms for stable or unstable symptoms at the Royal Adelaide and Queen Elizabeth Hospitals. All subjects will undergo guideline-recommended treatment of their coronary artery disease (CAD) at the direction of their treating clinicians. Eligible subjects will be those who have at least one major coronary artery system that will be left with residual coronary plaque. Following informed consent and within 30 days of their index angiogram, subjects will undergo further evaluation of their coronary plaque(s) by non-invasive computer tomography coronary angiography (CTCA), along with collection of clinical data and collection and storage of blood and faeces specimens (Baseline). They will return after 12±1 months for repeat CTCA imaging and collection of clinical information, blood and faeces (Follow-up).
We will assess for changes in coronary plaque burden and composition between baseline and follow-up CTCA scans, and examine for their associations with a range of established and exploratory clinical, biological and mechanical factors. An additional study visit will be conducted at 6 months to collect clinical information and conduct questionnaires related to quality-of-life, mental well-being and pain scores.
Aims/Objectives: To determine:
(1) Changes in noncalcified plaque volume between baseline and follow-up CTCA scans in patients with CAD.
(2) Changes in other CTCA-derived measures of coronary plaque burden and composition, between baseline and follow-up CTCA scans including: (i) total atheroma volume, (ii), calcified plaque volume, (iii) low attenuated plaque volume, (iv) percent atheroma volume, (v) maximum lumen stenosis, (vi) Leaman score, (vii) epicardial fat attenuation index and other (viii) novel plaque characteristics between baseline and 12-month follow-up.
(3) Changes in blood, urinary and faecal biomarkers of interest that may associate with the development and progression of atherosclerotic CAD, as well as associations with quality of life, mental well-being and the presence of cardiac and non-cardiac pain syndrome data.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
126046
0
A/Prof Peter Psaltis
Query!
Address
126046
0
SAHMRI, North Terrace, Adelaide SA 5000
Query!
Country
126046
0
Australia
Query!
Phone
126046
0
+61 0882184000
Query!
Fax
126046
0
Query!
Email
126046
0
[email protected]
Query!
Contact person for public queries
Name
126047
0
Dr Naomi Wattchow
Query!
Address
126047
0
SAHMRI, North Terrace, Adelaide SA 5000
Query!
Country
126047
0
Australia
Query!
Phone
126047
0
+61 437656853
Query!
Fax
126047
0
Query!
Email
126047
0
[email protected]
Query!
Contact person for scientific queries
Name
126048
0
Dr Naomi Wattchow
Query!
Address
126048
0
SAHMRI, North Terrace, Adelaide SA 5000
Query!
Country
126048
0
Australia
Query!
Phone
126048
0
+61 437656853
Query!
Fax
126048
0
Query!
Email
126048
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
pooled analysis of patient data will be studied
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF